CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to create a cell-based assay for screening new antifibrotic drugs targeting liver fibrosis and other chronic diseases. By utilizing a fluorescent tagging method, it seeks to enhance the identification of effective therapeutic compounds in preclinical settings.
Liver fibrosis (hepatitis B and C, cirrhosis, etc) represents an enormous health burden responsible for ~1.03 millions death per year worldwide according to the World Health Organization.
Fibrosis is also a common outcome of many chronic diseases of the kidney (diabetic nephropathy), lungs (idiopathic pulmonary fibrosis), heart and vasculature (heart failure).
In pathologies where fibrosis is a feature, there is an increased deposition of extracellular matrix proteins, including collagens that d…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
